CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based cancer therapies. Leveraging its proprietary Probody® technology platform, CytomX aims to create targeted treatments that selectively activate in the tumor microenvironment, minimizing damage to healthy tissues. The company’s pipeline includes novel immunotherapies and antibody-drug conjugates designed to address unmet medical needs in oncology. By advancing a new generation of precision medicines, CytomX Therapeutics is committed to improving outcomes for patients with cancer. The company collaborates with leading pharmaceutical partners to accelerate the development and commercialization of its therapeutic candidates, reinforcing its role as a pioneer in the field of targeted cancer therapy.
